Tempus AI Stock Price, News & Analysis

Tempus AI (NASDAQ: TEM) has announced its involvement in nearly 1,500 research projects over the past decade, demonstrating its commitment to advancing precision medicine through AI technology. The company's contributions include approximately 1,000 biopharma research projects and 500 provider-led research initiatives through its diagnostic portfolio and biological modeling capabilities.

Since its founding in 2015, Tempus has collaborated with academic institutions, health systems, and biopharma organizations, supporting over 200 projects with diagnostic assays and about 65 research initiatives through its biological modeling lab. The company's AI-powered platform provides comprehensive solutions for clinical and therapeutic research, focusing on therapy selection and drug discovery.

Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has published a study in Genetics in Medicine highlighting the success of their Patient for Life™ program. The program systematically reanalyzes exome test results, leading to a 5% diagnostic success rate for previously negative or uninformative cases. The study, analyzing cases from 2012-2021, revealed that 23% of cases underwent at least one reanalysis. Notably, 54% of lab-driven reanalyses resulted in diagnostic reclassification, compared to just 4% for clinician-requested reanalyses. The program's efficiency is demonstrated by the fact that 80% of reclassified cases identified new diagnoses that might have been missed without the laboratory-initiated workflow. This initiative is particularly significant given that rare diseases affect 25-30 million Americans, with over 100 new gene-disease associations discovered annually.

Tempus AI (NASDAQ: TEM), a technology company focused on AI-driven precision medicine and patient care, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The conference is scheduled for June 3-5, 2025 in Chicago, IL. The company's Chief Financial Officer, Jim Rogers, will deliver a presentation on June 5. The presentation will be accessible via a live audio webcast.

Tempus AI (NASDAQ: TEM) has announced a collaboration with Verastem Oncology to develop a companion diagnostic (CDx) test for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The partnership follows Tempus' successful confirmatory testing in Verastem's Phase 2 RAMP-201 trial, which led to the FDA's accelerated approval of the combination treatment using avutometinib and defactinib. Tempus' FDA-approved xT CDx assay is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 trial to assess KRAS status in LGSOC patients. LGSOC is a rare ovarian cancer affecting younger women, representing 6-10% of serous ovarian cancers, with high recurrence rates and poor chemotherapy response. The xT CDx test can detect alterations in 648 genes and microsatellite instability status using DNA from tumor tissue and matched normal specimens.

Tempus AI (NASDAQ: TEM) has announced a multi-year strategic collaboration with Boehringer Ingelheim to advance cancer research and drug development. The partnership will give Boehringer access to Tempus' de-identified database of molecular, clinical, and imaging data, along with its analytical platform, Lens.

The collaboration aims to leverage data and AI to guide biomarker development, patient stratification, drug combination hypotheses, and novel target discovery. This partnership builds on previous foundational work between the two companies, combining Boehringer's pre-clinical experimental data with Tempus' real-world data to enhance understanding of cancer biology and accelerate drug development.

Tempus AI (NASDAQ: TEM) announced the presentation of six research posters at ISPOR 2025 in Montreal, showcasing their work in AI and real-world data applications for healthcare. The presentations include one oral presentation on oncology trial emulation and five poster presentations focusing on: 1. Impact of adverse event definitions in immune-related events 2. Comparison of Tempus database with SEER cancer registry 3. Assessment of oncology treatment data completeness 4. NGS testing timing effects in colorectal cancer 5. Integration of sequencing, EHR, and claims data for lung cancer research The research demonstrates Tempus's efforts in combining clinical, molecular, and claims data to improve personalized cancer care and treatment strategies. Key findings include the impact of dataset features on trial emulations, varying immune-related adverse event detection rates, and the importance of timely NGS testing in survival outcomes.

Tempus AI reported strong Q1 2025 results with revenue surging 75.4% year-over-year to $255.7 million. Gross profit nearly doubled to $155.2 million, showing improved margins across segments. The company announced strategic collaborations with AstraZeneca and Pathos to develop oncology's largest multimodal foundation model, securing $200 million in additional fees over 3 years. Genomics revenue grew 88.9% to $193.8 million, while Data services revenue increased 43.2% to $61.9 million. Despite reporting a net loss of $68 million, Tempus raised its 2025 revenue guidance to $1.25 billion (80% YoY growth) and expects positive Adjusted EBITDA of $5 million, marking a $110 million improvement over 2024. Notable achievements include completing the Ambry Genetics acquisition, partnering with Illumina, acquiring Deep 6 AI, and launching olivia, an AI health concierge app.

Tempus AI (NASDAQ: TEM) has launched Notetaker, an AI-powered clinical assistant designed to help psychiatrists generate progress notes. The tool, available through Tempus Hub, automatically records and transcribes patient sessions, creating clinical notes that integrate with electronic health records. Notetaker features real-time transcription with specialized psychiatric terminology recognition, automatic clinical note generation, and care gap notifications with pharmacogenomic insights.

The platform supports over 30 languages including English, Spanish, and Chinese, with automatic language switching capabilities. It complements Tempus' existing mental health solutions, including the Tempus nP pharmacogenomic test and PRO™ patient reported outcome solution. The HIPAA-compliant system offers adjustable settings for telehealth, in-person sessions, and dictation.

Tempus AI (NASDAQ: TEM) is expanding its TIME Network's support for phase I clinical trials through the newly formed TIME Precision Network. The network connects over 40 phase I-capable research centers, focusing on rapid trial activation and enrollment. Notable achievements include: activating the Taylor Cancer Research Center (TCRC) in approximately two weeks for the Nimbus 9216-101 study with first patient enrollment within a month, and successfully enrolling the first two patients for the Pathos P300-02-001 study at Nebraska Cancer Specialists and Oncology Consultants within weeks. The TIME Network, established in 2019, leverages data integration to match patients with trials efficiently, with sites activated within days or weeks. The initiative aims to expand clinical trial access to underrepresented patient groups through community hospitals across the U.S.